Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Carina Bunschoten, Bart C. Jacobs, Peter Y.K. Van den Bergh, David Cornblath, Pieter A. van Doorn

Research output: Contribution to journalReview article

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosis. Nerve ultrasound and MRI could be helpful in diagnosis. Whereas typical CIDP is relatively easy to diagnose, atypical variants with distinct phenotypes can be a diagnostic challenge. Intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. Patients who do not improve, or insufficiently improve after treatment, might have specific characteristics related to a distinct disease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could require alternative treatments. Future studies should focus on curative and individualised treatment regimens to improve the patient's condition and to prevent further nerve damage.

Original languageEnglish (US)
Pages (from-to)784-794
Number of pages11
JournalThe Lancet Neurology
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Immunoglobulins
Therapeutics
Plasma Exchange
Neural Conduction
Diagnostic Errors
Adrenal Cortex Hormones
Phenotype
Antibodies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. / Bunschoten, Carina; Jacobs, Bart C.; Van den Bergh, Peter Y.K.; Cornblath, David; van Doorn, Pieter A.

In: The Lancet Neurology, Vol. 18, No. 8, 01.08.2019, p. 784-794.

Research output: Contribution to journalReview article

Bunschoten, Carina ; Jacobs, Bart C. ; Van den Bergh, Peter Y.K. ; Cornblath, David ; van Doorn, Pieter A. / Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. In: The Lancet Neurology. 2019 ; Vol. 18, No. 8. pp. 784-794.
@article{d1c102dffad64b2bb6294365ca9745ee,
title = "Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy",
abstract = "Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosis. Nerve ultrasound and MRI could be helpful in diagnosis. Whereas typical CIDP is relatively easy to diagnose, atypical variants with distinct phenotypes can be a diagnostic challenge. Intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. Patients who do not improve, or insufficiently improve after treatment, might have specific characteristics related to a distinct disease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could require alternative treatments. Future studies should focus on curative and individualised treatment regimens to improve the patient's condition and to prevent further nerve damage.",
author = "Carina Bunschoten and Jacobs, {Bart C.} and {Van den Bergh}, {Peter Y.K.} and David Cornblath and {van Doorn}, {Pieter A.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/S1474-4422(19)30144-9",
language = "English (US)",
volume = "18",
pages = "784--794",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "8",

}

TY - JOUR

T1 - Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy

AU - Bunschoten, Carina

AU - Jacobs, Bart C.

AU - Van den Bergh, Peter Y.K.

AU - Cornblath, David

AU - van Doorn, Pieter A.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosis. Nerve ultrasound and MRI could be helpful in diagnosis. Whereas typical CIDP is relatively easy to diagnose, atypical variants with distinct phenotypes can be a diagnostic challenge. Intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. Patients who do not improve, or insufficiently improve after treatment, might have specific characteristics related to a distinct disease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could require alternative treatments. Future studies should focus on curative and individualised treatment regimens to improve the patient's condition and to prevent further nerve damage.

AB - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosis. Nerve ultrasound and MRI could be helpful in diagnosis. Whereas typical CIDP is relatively easy to diagnose, atypical variants with distinct phenotypes can be a diagnostic challenge. Intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. Patients who do not improve, or insufficiently improve after treatment, might have specific characteristics related to a distinct disease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could require alternative treatments. Future studies should focus on curative and individualised treatment regimens to improve the patient's condition and to prevent further nerve damage.

UR - http://www.scopus.com/inward/record.url?scp=85068517684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068517684&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(19)30144-9

DO - 10.1016/S1474-4422(19)30144-9

M3 - Review article

C2 - 31076244

AN - SCOPUS:85068517684

VL - 18

SP - 784

EP - 794

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 8

ER -